LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 26, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will
report its fourth quarter and year-end 2014 financial results on March
12, 2015, before market open.
Following the announcement, management will host a conference call and
webcast at 8:30 a.m. ET that morning to discuss the fourth quarter
results and provide operational updates.
The conference call can be accessed by dialing (877) 407-8035 (U.S.) or
(201) 689-8035 (International). For those unable to join the live call,
a replay will be available from noon ET on March 12 through 11:59 p.m.
ET on March 19. To access the replay, please dial (877) 660-6853 (U.S.)
or (201) 612-7415 (International) and refer to conference ID 13602493.
The live webcast
can be accessed by visiting the Investor
Relations section of the Synta Pharmaceuticals website, www.syntapharma.com.
The webcast will also be archived under Webcasts
and Events within the Investor Relations section of the Company's
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical
company focused on research, development and commercialization of novel
oncology medicines that change cancer patients’ lives. Synta’s lead
oncology drug candidate, ganetespib, a novel heat shock protein 90
(Hsp90) inhibitor, is currently being evaluated in several clinical
trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell
lung cancer. Building on its extensive expertise in the science of
Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate
(HDC) small molecule drug development program. IND enabling studies have
commenced for the first clinical candidate from the HDC program,
STA-12-8666, and preclinical evaluation of additional HDC candidates is
ongoing. For more information, please visit www.syntapharma.com.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Andrea Rabney, 212-600-1494
Eliza Schleifstein, 917-763-8106